新器官受累是否应纳入 PSMA 成像的反应评估标准?

IF 2.5 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
İhsan Kaplan, Halil Kömek, Canan Can, Nadiye Akdeniz, Yunus Güzel, Ferat Kepenek, Ayhan Şenol, Serdar İleri, Hüseyin Karaoğlan, İhsan Solmaz, Mehmet Serdar Yıldırım, Veysi Şenses, Fulya Kaya, Cihan Gündoğan
{"title":"新器官受累是否应纳入 PSMA 成像的反应评估标准?","authors":"İhsan Kaplan,&nbsp;Halil Kömek,&nbsp;Canan Can,&nbsp;Nadiye Akdeniz,&nbsp;Yunus Güzel,&nbsp;Ferat Kepenek,&nbsp;Ayhan Şenol,&nbsp;Serdar İleri,&nbsp;Hüseyin Karaoğlan,&nbsp;İhsan Solmaz,&nbsp;Mehmet Serdar Yıldırım,&nbsp;Veysi Şenses,&nbsp;Fulya Kaya,&nbsp;Cihan Gündoğan","doi":"10.1007/s12149-024-01954-0","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>The current study is intended to investigate the effect of new organ involvement on overall survival (OS) and modify the Response Evaluation Criteria in PSMA Imaging (RECIP) by including new organ involvement to RECIP 1.0.</p><h3>Materials and methods</h3><p>This retrospective study includes 114 patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) between September 2017 and June 2022 who had received docetaxel treatment and had baseline and post-treatment prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) images. The inclusion criteria were patients with pre- and post-treatment [<sup>18</sup>F]FDG PET/CT images and whose [<sup>18</sup>F]FDG PET images were negative. Those whose data were unavailable, who had additional malignancy, or who received abiraterone, enzalutamide, or Lutetium (Lu)-177 treatment were excluded. Age, Gleason score (GS), TPSA (total prostate-specific antigen) levels, surgical history, and OS information were recorded for each patient.</p><h3>Results</h3><p>The 114 patients herein had a median age of 72.5 (51–91) years and a median GS of 8 (7–10). New lesions were observed in 59 patients (51.7%) and new organ PSMA uptake was observed in 14 patients (12.2%). In the multivariate Cox regression analysis, volume-based treatment response (vTR)-total lesion PSMA (TLP), RECIP PSMA-VOL, modified RECIP (mRECIP) PSMA-VOL, and mRECIP TLP were independent prognostic factors for mortality (<i>p</i> &lt; 0.001, <i>p</i> = 0.006, <i>p</i> = 0.003, and <i>p</i> = 0.003, respectively). The median OS of patients with new organ involvement and new lesion with PSMA uptake was 9.3 months (95% CI 2.1–16.5 months) and 11.8 months (95% CI 7.4–16.2 months), respectively.</p><h3>Conclusion</h3><p>The study concluded that new organ involvement had a shorter OS than new lesion involvement. In the mRECIP that we developed, unlike RECIP, we demonstrated that both PSMA-VOL and TLP value were independent prognostic factors for mortality.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Should new organ involvement be included in Response Evaluation Criteria in PSMA Imaging?\",\"authors\":\"İhsan Kaplan,&nbsp;Halil Kömek,&nbsp;Canan Can,&nbsp;Nadiye Akdeniz,&nbsp;Yunus Güzel,&nbsp;Ferat Kepenek,&nbsp;Ayhan Şenol,&nbsp;Serdar İleri,&nbsp;Hüseyin Karaoğlan,&nbsp;İhsan Solmaz,&nbsp;Mehmet Serdar Yıldırım,&nbsp;Veysi Şenses,&nbsp;Fulya Kaya,&nbsp;Cihan Gündoğan\",\"doi\":\"10.1007/s12149-024-01954-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><p>The current study is intended to investigate the effect of new organ involvement on overall survival (OS) and modify the Response Evaluation Criteria in PSMA Imaging (RECIP) by including new organ involvement to RECIP 1.0.</p><h3>Materials and methods</h3><p>This retrospective study includes 114 patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) between September 2017 and June 2022 who had received docetaxel treatment and had baseline and post-treatment prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) images. The inclusion criteria were patients with pre- and post-treatment [<sup>18</sup>F]FDG PET/CT images and whose [<sup>18</sup>F]FDG PET images were negative. Those whose data were unavailable, who had additional malignancy, or who received abiraterone, enzalutamide, or Lutetium (Lu)-177 treatment were excluded. Age, Gleason score (GS), TPSA (total prostate-specific antigen) levels, surgical history, and OS information were recorded for each patient.</p><h3>Results</h3><p>The 114 patients herein had a median age of 72.5 (51–91) years and a median GS of 8 (7–10). New lesions were observed in 59 patients (51.7%) and new organ PSMA uptake was observed in 14 patients (12.2%). In the multivariate Cox regression analysis, volume-based treatment response (vTR)-total lesion PSMA (TLP), RECIP PSMA-VOL, modified RECIP (mRECIP) PSMA-VOL, and mRECIP TLP were independent prognostic factors for mortality (<i>p</i> &lt; 0.001, <i>p</i> = 0.006, <i>p</i> = 0.003, and <i>p</i> = 0.003, respectively). The median OS of patients with new organ involvement and new lesion with PSMA uptake was 9.3 months (95% CI 2.1–16.5 months) and 11.8 months (95% CI 7.4–16.2 months), respectively.</p><h3>Conclusion</h3><p>The study concluded that new organ involvement had a shorter OS than new lesion involvement. In the mRECIP that we developed, unlike RECIP, we demonstrated that both PSMA-VOL and TLP value were independent prognostic factors for mortality.</p></div>\",\"PeriodicalId\":8007,\"journal\":{\"name\":\"Annals of Nuclear Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-06-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Nuclear Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s12149-024-01954-0\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12149-024-01954-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

摘要

目的:本研究旨在调查新器官受累对总生存期(OS)的影响,并通过将新器官受累纳入RECIP 1.0来修改PSMA影像学反应评估标准(RECIP):这项回顾性研究纳入了2017年9月至2022年6月期间诊断为转移性去势抵抗性前列腺癌(mCRPC)的114例患者,这些患者接受了多西他赛治疗,并具有基线和治疗后前列腺特异性膜抗原(PSMA)正电子发射断层扫描/计算机断层扫描(PET/CT)图像。纳入标准是具有治疗前和治疗后[18F]FDG PET/CT 图像且[18F]FDG PET 图像为阴性的患者。数据不详、患有其他恶性肿瘤或接受过阿比特龙、恩扎鲁胺或镥(Lu)-177 治疗的患者不在纳入之列。记录了每位患者的年龄、格里森评分(GS)、TPSA(总前列腺特异性抗原)水平、手术史和OS信息:114名患者的中位年龄为72.5(51-91)岁,中位GS为8(7-10)分。59名患者(51.7%)出现新病灶,14名患者(12.2%)出现新的器官PSMA摄取。在多变量考克斯回归分析中,基于容积的治疗反应(vTR)-总病灶 PSMA(TLP)、RECIP PSMA-VOL、改良 RECIP(mRECIP)PSMA-VOL 和 mRECIP TLP 是死亡率的独立预后因素(p 结论:该研究得出结论,新器官受累是导致癌症死亡的重要因素:该研究认为,新器官受累的 OS 短于新病灶受累的 OS。在我们开发的 mRECIP 中,与 RECIP 不同的是,我们证明 PSMA-VOL 和 TLP 值都是死亡率的独立预后因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Should new organ involvement be included in Response Evaluation Criteria in PSMA Imaging?

Should new organ involvement be included in Response Evaluation Criteria in PSMA Imaging?

Purpose

The current study is intended to investigate the effect of new organ involvement on overall survival (OS) and modify the Response Evaluation Criteria in PSMA Imaging (RECIP) by including new organ involvement to RECIP 1.0.

Materials and methods

This retrospective study includes 114 patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) between September 2017 and June 2022 who had received docetaxel treatment and had baseline and post-treatment prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) images. The inclusion criteria were patients with pre- and post-treatment [18F]FDG PET/CT images and whose [18F]FDG PET images were negative. Those whose data were unavailable, who had additional malignancy, or who received abiraterone, enzalutamide, or Lutetium (Lu)-177 treatment were excluded. Age, Gleason score (GS), TPSA (total prostate-specific antigen) levels, surgical history, and OS information were recorded for each patient.

Results

The 114 patients herein had a median age of 72.5 (51–91) years and a median GS of 8 (7–10). New lesions were observed in 59 patients (51.7%) and new organ PSMA uptake was observed in 14 patients (12.2%). In the multivariate Cox regression analysis, volume-based treatment response (vTR)-total lesion PSMA (TLP), RECIP PSMA-VOL, modified RECIP (mRECIP) PSMA-VOL, and mRECIP TLP were independent prognostic factors for mortality (p < 0.001, p = 0.006, p = 0.003, and p = 0.003, respectively). The median OS of patients with new organ involvement and new lesion with PSMA uptake was 9.3 months (95% CI 2.1–16.5 months) and 11.8 months (95% CI 7.4–16.2 months), respectively.

Conclusion

The study concluded that new organ involvement had a shorter OS than new lesion involvement. In the mRECIP that we developed, unlike RECIP, we demonstrated that both PSMA-VOL and TLP value were independent prognostic factors for mortality.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Annals of Nuclear Medicine
Annals of Nuclear Medicine 医学-核医学
CiteScore
4.90
自引率
7.70%
发文量
111
审稿时长
4-8 weeks
期刊介绍: Annals of Nuclear Medicine is an official journal of the Japanese Society of Nuclear Medicine. It develops the appropriate application of radioactive substances and stable nuclides in the field of medicine. The journal promotes the exchange of ideas and information and research in nuclear medicine and includes the medical application of radionuclides and related subjects. It presents original articles, short communications, reviews and letters to the editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信